论文部分内容阅读
药物基因组学以药物效应及安全性为目标,将基因的多态性与药物效应个体多样性紧密的联系在一起。药物基因组学研究不同于以往的基因研究,不是以发现新基因,阐明作用机制为目标,而是通过研究遗传因素对药物效应的影响,针对不同个体携带的基因型,给予不同的药物或剂量,以达到个体化治疗的目的。目前药物基因组学的研究主要是单核苷酸多态性(SNP)的研究,随着对药物作用机制分子水平的深入阐明,药物基因组学在抗癫痫药物、免疫抑制药、抗高血压药物、抗凝血药物、抗肿瘤药物等多个方面得到了较为广泛的研究。本文将对铂类、第三代细胞毒药物以及分子靶向药物等目前非小细胞肺癌常用一线治疗药物进行回顾,探讨药物基因组学用于指导晚期非小细胞肺癌一线治疗方
Pharmacogenomics aims at drug effects and safety, and closely correlates genetic polymorphisms with drug effects individual diversity. Pharmacogenomics research is different from the previous gene research, not to discover new genes, to clarify the mechanism of action as the goal, but through the study of genetic factors on the impact of drug effects, for different individuals carrying the genotype, given different drugs or doses, In order to achieve the purpose of individual treatment. At present, the research on pharmacogenomics mainly focuses on the study of single nucleotide polymorphism (SNP). With further elucidation of molecular mechanism of drug action mechanism, pharmacogenomics has been widely used in antiepileptic drugs, immunosuppressive drugs, antihypertensive drugs, Anticoagulant drugs, anti-tumor drugs and many other aspects have been more extensive research. This article reviews the current first-line therapies commonly used in non-small cell lung cancer such as platinum, the third generation of cytotoxic drugs and molecular targeted drugs to explore the use of pharmacogenomics to guide the first-line treatment of advanced non-small cell lung cancer